300765 CSPC Innovation Pharmaceutical
- 24.60
- -0.85-3.34%
CSPC Innovation Pharmaceutical News
New Novus: The Board\'s explanation on the purchase and sale of assets within 12 months prior to this transaction
New Novus: Explanation of the Board of Directors on the diluted immediate return situation, correction measures and commitments of this transaction
New Novus: Explanation of the Board of Directors that entities involved in this transaction are not allowed to participate in the major asset restructuring of listed companies in accordance with Article 12 of the “Supervisory Guidelines for Listed Companies No. 7 - Supervision of Abnormal Stock Transactions Related to Major Asset Restructuring of Listed Companies” and Section 30 of the “Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 8 - Major Asset Restructurings (2023 Revision)”
New Novus: The Board\'s explanation on the completeness of the transaction\'s compliance with legal procedures, compliance, and the effectiveness of submitting legal documents
New Novus: Explanation of the board of directors that this transaction constitutes a major asset restructuring as stipulated in Article 12 of the “Administrative Measures on Major Asset Reorganization of Listed Companies”, but does not constitute a restructuring and listing situation as stipulated in Article 13
New Novus: Explanation of the Board of Directors that this transaction complies with the provisions of Articles 18 and 21 of the “Measures for the Continued Supervision of Companies Listed on the GEM (Trial)” and Article 8 of the “Shenzhen Stock Exchange Listed Companies Major Asset Reorganization Review Rules”
New Novus: Board of Directors Explanation on Fluctuations in Stock Prices of Listed Companies Prior to Release of Information on the Transaction
New Novus: Instructions of the Board of Directors that the transaction complies with the relevant provisions of the “Administrative Measures on the Issuance and Registration of Listed Companies”
New Novus: Explanation of the Board of Directors on the confidentiality measures and confidentiality system adopted in this transaction
New Novus: Instructions of the board of directors that this transaction complies with the provisions of section 4 of the “Supervisory Guidelines for Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructurings”
New Novus: Instructions of the board of directors that this transaction complies with the provisions of Articles 11 and 43 of the “Administrative Measures on Major Asset Reorganization of Listed Companies”
CSPC Innovation Pharmaceutical: Explanation of the purchase and sale of assets within the last 12 months prior to this trade.
CSPC Innovation Pharmaceutical: Explanation on this trade that complies with Article 11 and Article 43 of the Measures for the Administration of Major Asset Restructuring of Listed Companies.
CSPC Innovation Pharmaceutical: Explanation that the adjustment of the pricing reference date for this trade proposal does not constitute a significant adjustment.
CSPC Innovation Pharmaceutical: This trade complies with the regulations of Article 4 of the Supervision Requirements for Major Asset Restructurings of Listed Companies in Compliance with the Guidelines for the Supervision of Listed Companies.
CSPC Innovation Pharmaceutical: Explanation of the confidentiality measures and system adopted for this trade.
CSPC Innovation Pharmaceutical: This trade complies with relevant regulations of the Securities Issuance and Registration Management Measures for Listed Companies.
CSPC Innovation Pharmaceutical: Regarding this trade, it is expected to constitute a significant asset restructuring under Article 12 of the "Management Measures for Major Asset Restructuring of Listed Companies", but it does not constitute a case of restructuring for listing under Article 13.
CSPC Innovation Pharmaceutical: The explanation of this transaction is in compliance with Article 18 and 21 of the Measures for the Continuous Supervision of Listed Companies on the Growth Enterprise Market (Trial), as well as Article 8 of the Shenzhen Stock Exchange's Rules for the Review of Major Asset Restructurings of Listed Companies.
CSPC Innovation Pharmaceutical: Explanation regarding the completeness, compliance, and effectiveness of the legal procedures and submission of legal documents for this trade.
No Data
